Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for HIV Treatment, to Third Party Payers in the United States
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.128
https://www.valueinhealthjournal.com/article/S1098-3015(13)02033-0/fulltext
Title :
Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for HIV Treatment, to Third Party Payers in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02033-0&doi=10.1016/j.jval.2013.08.128
First page :
A343
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
114